Illinois Tool Works vs Kimberly-Clark
Diversified industrial manufacturer with steady cash flow vs Global maker of tissue and personal care products. Which is the better buy for your portfolio in September 2026? Plain-English answer below.
Illinois Tool Works runs a decentralized empire of industrial manufacturing businesses serving aerospace, automotive, and construction markets with highly engineered components, while Kimberly-Clark sells tissue, diapers, and personal care products to consumers and healthcare facilities worldwide under globally recognized brands. Both companies have prioritized consistent dividend growth and margin discipline over headline revenue expansion, making them cornerstones of dividend-focused portfolios. Illinois Tool Works vs Kimberly-Clark explores how two blue-chip dividend growers pursue the same shareholder return goals from opposite ends of the industrial and consumer spectrum.
Illinois Tool Works runs a decentralized empire of industrial manufacturing businesses serving aerospace, automotive, and construction markets with highly engineered components, while Kimberly-Clark s...
Why It’s Moving
ITW’s Earnings Beat Fails to Clear the Analyst Caution Hanging Over Shares
- Second-quarter earnings came in at $2.84 per share, $0.04 above consensus, while revenue reached $4.30 billion, up 6.1% year over year—evidence of steady operating momentum.
- ITW raised its quarterly dividend to $1.72 per share from $1.61, signaling confidence in cash generation and adding support for income-focused investors.
- Analyst sentiment remained cautious, with 13 firms carrying a consensus Reduce rating; that skepticism helps explain why shares weakened despite the earnings beat and dividend increase.
KMB’s Kenvue takeover hits a fresh regulatory hurdle as near-term operating pressure builds.
- EU regulators are expected to raise antitrust concerns this week, and Kimberly-Clark is preparing possible asset sales to win approval for its roughly $40 billion Kenvue acquisition. That could reduce the risk of a prolonged review, but may also trim some of the deal’s strategic benefits.
- At the September 9 Barclays conference, management cited China weakness, a delayed North American innovation launch, distributor disruption and higher freight costs as near-term pressures. The comments suggest the company’s longer-term innovation and margin plans are competing with softer current operating momentum.
- Australia approved the Kenvue transaction with divestment conditions on September 8, providing a regulatory precedent while underscoring that additional concessions may be required in other markets. Investors are weighing the potential consumer-health expansion against added integration, regulatory and execution complexity.
ITW’s Earnings Beat Fails to Clear the Analyst Caution Hanging Over Shares
- Second-quarter earnings came in at $2.84 per share, $0.04 above consensus, while revenue reached $4.30 billion, up 6.1% year over year—evidence of steady operating momentum.
- ITW raised its quarterly dividend to $1.72 per share from $1.61, signaling confidence in cash generation and adding support for income-focused investors.
- Analyst sentiment remained cautious, with 13 firms carrying a consensus Reduce rating; that skepticism helps explain why shares weakened despite the earnings beat and dividend increase.
KMB’s Kenvue takeover hits a fresh regulatory hurdle as near-term operating pressure builds.
- EU regulators are expected to raise antitrust concerns this week, and Kimberly-Clark is preparing possible asset sales to win approval for its roughly $40 billion Kenvue acquisition. That could reduce the risk of a prolonged review, but may also trim some of the deal’s strategic benefits.
- At the September 9 Barclays conference, management cited China weakness, a delayed North American innovation launch, distributor disruption and higher freight costs as near-term pressures. The comments suggest the company’s longer-term innovation and margin plans are competing with softer current operating momentum.
- Australia approved the Kenvue transaction with divestment conditions on September 8, providing a regulatory precedent while underscoring that additional concessions may be required in other markets. Investors are weighing the potential consumer-health expansion against added integration, regulatory and execution complexity.
Investment Analysis
Pros
- Illinois Tool Works achieved record operating margins of 27.4% in Q3 2025, driven by strong operational efficiency and margin expansion initiatives.
- The company reported a 6% year-over-year increase in earnings per share and a 15% growth in free cash flow with excellent conversion rates.
- ITW benefits from diversified industrial segments including Automotive OEM and Food Equipment, supporting steady revenue growth despite modest top-line increases.
Considerations
- Revenue growth is modest, with only a 2% increase year-over-year and some segments showing flat or negative performance.
- The stock price declined following earnings due to slightly missed revenue forecasts and cautious investor sentiment despite strong earnings.
- Valuation metrics reflect elevated multiples, with a price-to-earnings ratio near 24 and a dividend payout ratio that may constrain reinvestment potential.
Pros
- Kimberly-Clark has a portfolio of strong consumer brands with global recognition, supporting steady demand in personal care and hygiene products.
- The company maintains stable free cash flow generation and a disciplined dividend policy attractive to income-focused investors.
- Efforts in innovation and sustainability initiatives are helping to improve operational efficiencies and align with consumer trends.
Considerations
- Exposure to commodity cost inflation, particularly pulp and packaging materials, can pressure margins in the near term.
- Growth is challenged by mature market saturation and competitive pressure in core categories, limiting top-line expansion.
- Economic sensitivity in emerging markets and currency fluctuations create volatility risks for international revenue streams.
Illinois Tool Works (ITW) Next Earnings Date
Illinois Tool Works (ITW) is expected to report its next earnings on October 23, 2026, although the date has not been officially confirmed. The report will cover the third quarter of fiscal 2026, ended September 30, 2026. The timing is consistent with ITW’s typical late-October quarterly reporting pattern.
Kimberly-Clark (KMB) Next Earnings Date
Kimberly-Clark (KMB) is currently expected to report its next earnings on October 29, 2026. The release should cover the company’s third quarter of fiscal 2026, ended September 30. The date remains an estimate rather than a formally confirmed company announcement.
Illinois Tool Works (ITW) Next Earnings Date
Illinois Tool Works (ITW) is expected to report its next earnings on October 23, 2026, although the date has not been officially confirmed. The report will cover the third quarter of fiscal 2026, ended September 30, 2026. The timing is consistent with ITW’s typical late-October quarterly reporting pattern.
Kimberly-Clark (KMB) Next Earnings Date
Kimberly-Clark (KMB) is currently expected to report its next earnings on October 29, 2026. The release should cover the company’s third quarter of fiscal 2026, ended September 30. The date remains an estimate rather than a formally confirmed company announcement.
Buy ITW or KMB in Nemo
Zero Commission
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Trusted & Regulated
Part of Exinity Group 2015, serving over a million customers globally.
6% Interest on Cash
Earn 6% AER on uninvested cash with daily interest payments.
